Patient Care

Clinical Application of Next Generation Sequencing Testing
CME (AMA PRA Category 1 Credits™) 2.0; Attendance CEU 2.0; 2.0 MOC
Learn More

Sunday, October 8
3:30 PM - 5:30 PM

This session will highlight the use of specialized testing (including NGS) in the diagnosis and/or treatment of patients with brain tumors and hematologic malignancies. Case presentations will include discussion by both laboratory and clinical experts.

Mayo Clinic Gonda Building

3:30 p.m.–Clinical Genomic Characterization of Adult Gliomas
4:30 p.m.–Clinical Ramification of NGS in Myeloid Neoplasms: Diagnosis, Prognosis, and Prediction

https://news.mayomedicallaboratories.com/2017/07/07/clinical-application-next-generation-sequencing-ngs-testing/

“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through PARS."



Learning Objectives:

Benjamin Kipp

Associate Professor of Laboratory Medicine and Pathology
Mayo Clinic

Presentation(s):

Send Email for Benjamin Kipp

Robert Jenkins

Department of Laboratory Medicine and Pathology
Mayo Clinic

Robert B. Jenkins, MD, PhD, professional career has been focused on cancer genetics, particularly elucidation of the genetic events important for cancer initiation and progression. His cancer genetics efforts have encompassed both basic genetic investigations as well as clinical translation of those basic genetic observations. Dr. Jenkins' primary interest has been centered on the genetics of gliomas, where both his basic genetic studies and clinical translation activities have had a major impact on neuro-oncology. The Jenkins lab has worked in other areas of neuro-oncology. For example, his lab discovered that 1p/19q codeletion is assocaited with tumors of olidogendroglial lineage and predicts response to chemotherapy and radiation therapy. They also developed a FISH test that is used world-wide to test for these deletions. They developed carrier peptides to deliver proteins and small molecules across the blood-brain barrier (BBB). This technology has been licensed by several drug companies and is showing evidence of success for the treatment of neurologic disorders. The lab has developed new diagnostic and predictive tests for use in for various cancers. The Jenkins lab was involved in the development of the FDA-approved dual-probe fluorescence in situ hybridization (FISH) test that is used to stratify patients for the treatment with HER2 targeted therapies. With the company Genome Diagnostics Inc. they developed an expression profiling test that predicts which men with prostate cancer are likely to develop clinical progression. This test is now included in the NCCN prostate cancer diagnostic guidelines. Dr. Jenkins has been involved in the development of several other genetic tests, including multiple FISH and array comparative genomic hybridization (aCGH) tests. In the CIM conference he will be discussing the development of mate-pair NGS for use as a clinical cytogenetics test.

Presentation(s):

Send Email for Robert Jenkins

Daniel H. Lachance

Associate Professor of Neurology
Mayo Clinic

Daniel Lachance, MD, is a clinical neuro-oncologist with daily patient contact, a member of the Mayo Clinic staff since January 1999, and chair of the Division of Neuro-Oncology in the Department of Neurology since 2009. He holds a joint appointment in the Division of Clinical Biochemistry & Immunology, Department of Laboratory Medicine and Pathology, Neuro-Immunology Laboratory, with a special interest in paraneoplastic autoimmune neurology. Since 2011 Dr. Lachance has directed the Clinical Core of the Mayo Brain SPORE, and has also been clinical co-PI with Robert Jenkins for SPORE Project 4: Clinical Relevance of Chromosome 5p/9p/20q/8q Germline Alterations in Gliomas. His neuro-oncology training was at Duke university Medical Center, residency training at Mayo Clinic. Dr. Lachance attended Dartmouth Medical School with his undergrad work at Dartmouth College. Originally from Fall River, Massachusetts.

Presentation(s):

Send Email for Daniel Lachance

Rong He

Consultant, Division of Hematopathology
Mayo Clinic

Rong He, MD, is a hematopathologist at Mayo Clinic in Rochester, MN. She is a consultant and assistant professor in the Division of Hematopathology, and a co-director of the Molecular Hematopathology Laboratory. Besides her slides-based diagnostic work, Dr. He has developed and improved multiple molecular tests for hematologic malignancies, using various technologies including next generation sequencing. Her professional interests center on diagnostic pathology of myeloid neoplasms, molecular test development for hematologic neoplasm diagnostics and prognostics, as well as thrombosis and hemostasis.

Presentation(s):

Send Email for Rong He

Aref Al-Kali

Assistant Professor of Medicine
Mayo Clinic
Mayo Clinic

Aref Al-Kali, PhD, is an Assistant Professor in the division of Hematology/Department of Internal Medicine at Mayo Clinic and the Co-Director of leukemia fellowship at Mayo Clinic Rochester. He is a member of the American Society of Hematology and American Society of Clinical Oncology.

Presentation(s):

Send Email for Aref Al-Kali


Assets

Clinical Application of Next Generation Sequencing Testing
CME (AMA PRA Category 1 Credits™) 2.0; Attendance CEU 2.0; 2.0 MOC



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Clinical Application of Next Generation Sequencing Testing
CME (AMA PRA Category 1 Credits™) 2.0; Attendance CEU 2.0; 2.0 MOC